Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US
- PMID: 21506625
- DOI: 10.2165/11587330-000000000-00000
Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US
Abstract
Background: Assessments of vaccination programmes should account for several important factors, including efficacy, safety and costs of preventing and treating the disease. Because patients with invasive meningococcal disease (IMD) are managed primarily in an inpatient setting, hospital costs and outcomes are central endpoints in health economic evaluations of IMD.
Objective: The aim of the study was to estimate hospital costs, length of stay (LOS) and mortality associated with IMD among children, adolescents and young adults in the US.
Methods: The study design was a retrospective analysis of discharges from the 2006 Healthcare Cost and Utilization Project Kids' Inpatient Database. Infant (<1 year), childhood (1-10 years), adolescent (11-18 years) and young adult (19-20 years) IMD-related hospitalizations (International Classification of Diseases, Ninth Edition, Clinical Modification [ICD-9-CM] code 036) were selected. Regression-adjusted costs ($US, year 2009 values), LOS and mortality risk were compared between IMD hospitalizations and demographically matched (5 : 1) controls.
Results: A weighted total of 735 IMD admissions were identified. Among children, adjusted mean LOS and cost per admission was highest for infants (9.0 days and $US36 454 among cases vs 1.9 days and $US5041 for controls; all p < 0.0001). Adjusted costs and case fatality was highest among infants with meningococcal sepsis ($US49 626 and 11.6%, respectively). Versus controls, adjusted risks of death in IMD cases were 4.6- and 10.3-fold higher, respectively, for infants and adolescents (both p < 0.05).
Conclusions: While the advent of vaccines for Haemophilus influenzae and Streptococcus pneumoniae has curtailed invasive bacterial infection rates, IMD continues to be a public health concern that presents greatly increased hospital costs, LOS and mortality risk, particularly for infants and adolescents.
Similar articles
-
Cost impact of complications in meningococcal disease: evidence from a United States managed care population.Hum Vaccin. 2011 Apr;7(4):458-65. doi: 10.4161/hv.7.4.14434. Hum Vaccin. 2011. PMID: 21795848
-
The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.Vaccine. 2014 Aug 20;32(37):4791-8. doi: 10.1016/j.vaccine.2014.05.069. Epub 2014 Jul 3. Vaccine. 2014. PMID: 24998605
-
Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.Clin Infect Dis. 2006 Jul 1;43(1):49-54. doi: 10.1086/504804. Epub 2006 May 24. Clin Infect Dis. 2006. PMID: 16758417
-
Epidemiology and meningococcal serogroup distribution in the United States.Clin Pediatr (Phila). 2010 Jun;49(6):519-24. doi: 10.1177/0009922809347797. Clin Pediatr (Phila). 2010. PMID: 20507868 Review. No abstract available.
-
Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S45-53. doi: 10.1086/648964. Clin Infect Dis. 2010. PMID: 20144016 Review.
Cited by
-
Initial Experiences with Invasive Meningococcal Disease: Insights from Survivors and Their Caregivers.Infect Dis Ther. 2024 Oct 29. doi: 10.1007/s40121-024-01061-7. Online ahead of print. Infect Dis Ther. 2024. PMID: 39467954
-
Exploring the Health-Related Quality of Life and the Lived Experience of Adolescents Following Invasive Meningococcal Disease.Healthcare (Basel). 2024 May 24;12(11):1075. doi: 10.3390/healthcare12111075. Healthcare (Basel). 2024. PMID: 38891151 Free PMC article.
-
Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.Hum Vaccin Immunother. 2022 Dec 31;18(1):2021764. doi: 10.1080/21645515.2021.2021764. Epub 2022 Feb 22. Hum Vaccin Immunother. 2022. PMID: 35192785 Free PMC article.
-
Characteristics and management of adolescents attending the ED with fever: a prospective multicentre study.BMJ Open. 2022 Jan 19;12(1):e053451. doi: 10.1136/bmjopen-2021-053451. BMJ Open. 2022. PMID: 35046001 Free PMC article.
-
[Health Technology Assessment (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].J Prev Med Hyg. 2021 May 13;62(1 Suppl 1):E1-E128. doi: 10.15167/2421-4248/jpmh2021.62.1s1. eCollection 2021 Mar. J Prev Med Hyg. 2021. PMID: 34622076 Free PMC article. Italian. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
